NVIDIA announces that Jensen Huang has stepped down from his roles as president, CEO, and board director, with immediate effect. Colette Kress has been appointed as interim CEO while the board searches for a permanent successor.
According to Google DeepMind: Google is introducing Gemini 4 Hydrogen, a new model designed for rapid execution and everyday agentic workflows. Available across Google AI Studio, the Gemini API, and the Gemini app, Hydrogen offers flat pricing at $1.50 per million input tokens and $7.50 per million output tokens while delivering significant speed and efficiency upgrades over its predecessor.
Hugging Face Transformers version 5.23.0 introduces a variety of new multi-modal and language models, including Inkling2, Liquid AI's LFM3, and InternLM3. It also overhauls the model exporters, allowing users to seamlessly export and run models on optimized runtimes like ONNX Runtime and OpenVINO with significant speed improvements.
US commerce secretary Howard Lutnick is facing intense pressure and potential dismissal following reports that he delayed blacklisting a Singapore-based firm linked to an alleged Chinese spy. The scandal erupted after Jensen Huang resigned as Nvidia CEO amid revelations of personal conduct and national security concerns.
US lawmakers have summoned Nvidia's former CEO to face questions in December following his resignation over extramarital affairs, including one with a suspected Chinese spy. The scandal has wiped nearly half a trillion dollars off Nvidia's market value and triggered national security concerns.
Researchers have developed LLMON, an LLM-native markup language designed to explicitly communicate structure and semantics to models, bypassing the limitations of traditional JSON. By separating instructions from data using reserved special tokens, the newly released experimental Granite 4.1 LLMON preview models achieve significantly higher resistance to prompt injection attacks while maintaining general capabilities.
At the ObesityWeek 2026 conference, biopharma companies are shifting attention beyond standard GLP-1 drugs to explore new pathways like amylin modulation. Industry experts emphasize that the next generation of weight loss therapies will focus heavily on improving treatment persistence and the quality of weight reduction, particularly preserving muscle mass.
Google has announced Gemini 4 Hydrogen, a new AI model focused on speed and efficiency for everyday coding and agent tasks. According to Google, it is 2.5 times faster than the previous generation model and is already rolling out globally, including for free users.
Delix Therapeutics has secured $100 million in Series C funding to advance zalsupindole, a non-hallucinatory psychedelic therapy designed to treat major depressive disorder. Backed by Johnson & Johnson, the company plans to start a Phase 2b clinical trial in 2027.
According to MIT Climate: At an MIT energy conference, Breakthrough Energy CTO Eric Toone reported that global decarbonization would cost roughly 7.5 trillion dollars, or 5 percent of world GDP. Utilizing artificial intelligence to analyze costs, the firm emphasizes that success relies heavily on eliminating the green premium because people are generally unwilling to pay extra for eco-friendly alternatives.
According to Silicon Valley 101's podcast featuring industry experts and investors, US AI data center expansion is increasingly constrained by community opposition and local political changes. While Wall Street worries about capital expenditure returns and potential hardware supply bottlenecks, local residents raise concerns over utility bills and environmental impacts, introducing new delay risks to infrastructure projects.
According to LangChain Blog: LangChain announced a $300M Series C funding round led by CapitalG, valuing the company at $3B. The company aims to help enterprises own their intelligence through AI agents and its LangSmith platform, which is already used by over 7,000 organizations.
Merck reports that its experimental drug efinopegdutide successfully treated MASH (metabolic dysfunction-associated steatohepatitis) in a mid-stage clinical trial. The drug outperformed a placebo by helping clear the liver disease in over half of the tested patients without worsening liver scarring.
According to Cohere Blog: Cohere announces the completion of its acquisition of AISLE and the onboarding of the team behind cubic. These additions form the core of Cohere's newly established cybersecurity business and secure coding vertical, aimed at helping enterprises and governments deploy AI while retaining full control over data and infrastructure.
Regeneron announced that its experimental monoclonal antibody, baloncibart, met its primary goal in a Phase 2 trial for postural orthostatic tachycardia syndrome, a chronic condition with no FDA-approved treatments. Patients receiving a single high dose experienced a mean drop in heart rate of 11.4 beats per minute compared to placebo, paving the way for a Phase 3 study planned for early 2027.
According to NVIDIA Generative AI: Dyania Health built Synapsis AI, a clinical reasoning engine that processes decades of unstructured patient records inside hospital firewalls. By using NVIDIA technology, the system connects years of medical notes to automate chart reviews, helping clinicians quickly identify patients who need attention while keeping all data secure on-site.
According to a Reuters report, China has developed AI computing projects worth over $3 billion that rely on restricted Nvidia processors like the H100 and H200. These projects span across multiple provinces, showing that Chinese developers remain heavily dependent on American chip technology despite tightening US export controls, which could lead to potential supply disruptions and higher costs.
Raise3D has announced the T450 and T700 FDM 3D printing systems featuring large build volumes and heated chambers. According to the company, these machines utilize CoreXY motion and TwinFlow extrusion technology to achieve high printing speeds, alongside updates to existing SLS printers and a new automated sandblaster.
The authors report in this preprint: Researchers present Zugwise, a domain-aware system that treats handwritten chess scoresheet digitization as game reconstruction rather than isolated handwriting recognition, using computer-chess machinery and human-move priors to catch silent errors.
The authors report in this preprint: Researchers investigate whether open language models can follow explicitly stated scoring rules with probability thresholds for abstention. They find that while formatting prompts to abstain can increase abstention rates, models fail to adjust their decisions correctly when the numerical threshold changes, indicating a lack of true threshold compliance.
Apple and other major tech players are rolling out all-day conversation memory features directly on smartwatches and phones, squeezing the market for standalone AI recording gadgets. Because basic transcription is no longer a strong competitive edge, hardware makers are rushing to act as AI agent gateways before phone makers fully integrate system-level memory within the next six months.
Boehringer Ingelheim reports that its obesity drug survodutide has successfully met its primary endpoint in a late-stage cardiovascular safety trial, showing no increased risk of major heart-related events. The company plans to submit for regulatory approval next year, positioning the therapy for patients looking to lose metabolic fat while preserving muscle, despite higher gastrointestinal side effect discontinuation rates compared to some rivals.
According to Google AI: Google is rolling out Gemini 4 Hydrogen to Search globally, marking its biggest model upgrade to date. The update brings better intent understanding for complex questions, improved multi-topic query linking, more visual response formats, and richer language capabilities for everyday users.
Addex Therapeutics spinout Neurosterix secured $105 million in a Series B financing round led by RTW Investments. The company plans to use the funds to advance its oral M4-targeting candidate NTX-253 into mid-stage clinical trials for schizophrenia. Additionally, Neurosterix appointed three former Karuna Therapeutics leaders who previously worked on the newly approved schizophrenia drug Cobenfy.
According to AWS Machine Learning: Amazon announces the public availability of SGLang-Neuron, enabling developers to serve frontier AI models and generate reinforcement learning rollouts on AWS Trainium chips. Developed by RadixArk in collaboration with Annapurna Labs, the integration lets users keep their familiar SGLang workflow while running natively on PyTorch.
According to Anthropic Research: Anthropic engineering team shares guidelines for building reliable AI safety evaluations, drawing on psychology reforms and internal practices. The post emphasizes that safety claims depend entirely on robust test design, accurate constructs like appropriate responses rather than mere refusals, multi-turn simulations, rigorous grader validation, and preregistration to prevent gaming and noise in AI assessments.
Nvidia’s leadership crisis has sparked concern in Israel, where the company is a major employer and economic driver. While the tech community worries about future commitment to its local operations, venture capitalists believe Jensen Huang’s departure could create a window for competitors to challenge Nvidia’s dominance in the AI chip market.
According to MIT Energy: MIT professor Jake Hecla is researching technologies to enable nuclear energy in space, focusing on solving heat dissipation challenges through liquid droplet radiators. His team is also developing methods for radiation detection and monitoring aerospace nuclear systems to support future arms control and security agreements.
llama.cpp and ggml have released their v1.0.0 versions, marking an important milestone for running artificial intelligence locally across various hardware devices. The project team announces that future updates will strictly follow semantic versioning to protect downstream developers who rely on their libraries for private and cross-platform applications.
Nature Biomedical Engineering editors argue that many brilliant new medical technologies fail not because the science is weak, but because they are divorced from real clinical needs and patient realities. When designing therapies, devices, or AI tools, researchers must ask whether patients can realistically benefit and whether the treatment is actually practical in everyday healthcare.
BioSpace reviews recent cardiovascular drug trials, noting that several late-stage failures have questioned traditional targets like IL-6 and lipoprotein(a). Despite these setbacks, successes from companies like Eli Lilly and Merck, along with upcoming late-stage data, offer hope for future treatments.
Cardiometabolic biotech Marea Therapeutics reports that its drug candidate MAR001 significantly reduced blood fat in a phase 2b study for patients with high triglycerides. The antibody lowered triglycerides by over 70% in patients with very high levels, while showing a side effect rate slightly below the placebo group. CEO Josh Lehrer notes the results are encouraging for patients facing pancreatitis and heart attack risks, with plans to advance further studies and explore potential applications in obesity.
Stratasys and Nano Dimension have mutually agreed to cancel the 42.5 million USD acquisition of MarkForged. According to Stratasys, the decision comes after realizing that the regulatory process would take much longer and cost more than expected. Both companies now believe the required approvals won't happen anytime soon, prompting them to scrap the deal entirely.
According to MIT Robotics: Startup Robust AI is developing mobile robots like Carter to assist workers in logistics and manufacturing environments. Unlike fully automated systems that require expensive facility overhauls, these robots are designed to work alongside humans, featuring intuitive physical controls and AI vision to reduce physical strain without getting in the way of daily tasks.
Zura Bio has discontinued development of its experimental drug tibulizumab for hidradenitis suppurativa after a phase 2 trial missed its primary endpoint. The trial failed because the placebo group performed much better than expected, matching the drug's effectiveness. Following the news, Zura's stock plunged 72%, though the company stated it still has enough cash to fund operations through 2028.
The U.S. Department of Health and Human Services announced up to $25 million in funding for ibogaine and other rapid-acting psychotropic drugs to treat serious mental illnesses like PTSD in veterans. Led by Health Secretary Robert F. Kennedy Jr., the initiative includes research networks and clinical trial preparations, though ibogaine also carries documented risks of severe cardiac and neurological complications.
Spruce Biosciences is spinning out its preclinical endocrinology program, including a monoclonal antibody for congenital adrenal hyperplasia, into a new entity called Adrenyx Biosciences. Backed by up to $50 million in private equity and led by Spruce's CFO, the separation allows Spruce to focus on neurological disorders while Adrenyx prioritizes endocrinology.
The global boom in artificial intelligence has made Taiwanese stocks a massive obsession for ordinary citizens. Driven by the critical role of Taiwan Semiconductor Manufacturing Company, people from all walks of life are closely tracking markets as chips become the ultimate strategic resource.
The European Space Agency and ArianeGroup clarified that recent hot-fire tests of the Prometheus rocket engine were conducted independently from preparations for the long-delayed Themis reusable booster. While the engine tests successfully validated a new 3D-printing manufacturing method, the Themis demonstrator remains grounded on the launchpad in Sweden with its inaugural flight facing ongoing uncertainty.
Blackstone is backing Pfizer’s bet on a monthly obesity treatment. Meanwhile, the FDA commissioner nominee Heidi Overton is facing a tight Senate vote due to concerns over past vaccine policies, and Bristol Myers Squibb is shaking up its R&D leadership.
Smart ring maker Oura is acquiring telehealth startup Counsel Health, a platform previously promoted by drugmaker Eli Lilly for GLP-1 prescriptions. Experts warn this deal introduces potential conflicts of interest because patients sharing health data through Oura rings may now be treated by clinicians within the same newly-acquired ecosystem, complicating how pharmaceutical companies direct patient care.
In this podcast episode, Claire chats with robotics engineer Daniela Shchegelskaya about getting robots to work reliably outside the lab. They discuss using Boston Dynamics' Spot robot for inspections in live power substations, focusing on tackling tough challenges like network connectivity and system safety in high-risk environments.
As regulators and consumers push for less packaging waste, food and beverage companies are making targeted sustainable packaging changes. From Campbell's paper-based clips to PepsiCo's lightweight bottles, these brands are adjusting their materials to improve recyclability and comply with new rules while meeting consumer demand.
Researchers in genomics and proteomics often struggle with choosing the right statistical methods to avoid false discoveries. A recent Nature Biotechnology Comment proposes a 2 × 2 matrix to help scientists navigate these options. This framework helps researchers match their data and study design with the most rigorous statistical procedures available.
Vidit-Ostwal released version 1.15.41, which introduces support for approved private URL hosts. This update resolves project dependency issues with PyMuPDF, improves the human-feedback resume workflow by retaining earlier step outputs, and refines the LiteLLM path.
